论文部分内容阅读
目的比较依达拉奉与低分子肝素钙治疗急性脑梗死的临床疗效。方法将符合诊断标准的100例急性脑梗死患者随机分为治疗组和对照组,每组各50例。两组患者均给予基础对症治疗。治疗组在此基础上加用依达拉奉,将30 mg依达拉奉加入100 ml 0.9%氯化钠注射液静脉滴注,2次/d,30 min滴完。对照组在对症治疗基础上加用低分子肝素钙注射液,按0.1 ml/10 kg每12 h皮下注射1次。两组均以7 d为1个疗程,治疗2个疗程后观察疗效。结果治疗组痊愈率、总有效率分别为52.00%、92.00%,对照组痊愈率、总有效率分别为38.00%、82.00%,两组相比有统计学意义(P<0.05)。两组神经功能缺损程度评分(NDS)治疗后与治疗前相比均有所下降(P<0.05或P<0.01);治疗后治疗组神经功能缺损评分明显低于对照组(P<0.05)。两组均未发生严重不良反应。结论依达拉奉治疗急性脑梗死的疗效较低分子肝素钙好,可显著降低神经功能缺损评分,且无严重不良反应。
Objective To compare the clinical efficacy of edaravone and low molecular weight heparin in the treatment of acute cerebral infarction. Methods 100 patients with acute cerebral infarction who met diagnostic criteria were randomly divided into treatment group and control group, with 50 cases in each group. Two groups of patients were given basic symptomatic treatment. On the basis of this, edaravone was added to the treatment group, and 30 mg edaravone was added to 100 ml 0.9% sodium chloride injection twice a day for 30 min. The control group on the basis of symptomatic treatment plus low molecular weight heparin injection, press 0.1 ml / 10 kg subcutaneously once every 12 h. Both groups were 7 days for a course of treatment, after 2 courses of treatment to observe the effect. Results The cure rate and total effective rate in the treatment group were 52.00% and 92.00% respectively. The cure rate and total effective rate in the control group were 38.00% and 82.00% respectively, with statistical significance (P <0.05). The score of neurological deficit (NDS) decreased after treatment in both groups (P <0.05 or P <0.01). After treatment, the score of neurological deficit in treatment group was significantly lower than that in control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Edaravone has a lower curative effect on acute cerebral infarction than that of low molecular weight heparin, which can significantly reduce the score of neurological deficit without serious adverse reactions.